Payment overview · 2025
General Payments
$125.00
1 reported records · 1 companies
Healthcare provider profile · identity verified
Mercely Rani Devabavus, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · SPRING HILL, FL · NPI 1164611349
Verified facts
What the public records show
CMS Open Payments records show Mercely Rani Devabavus, M.D received $125.00 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $125.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 758 | 196 |
| Levothyroxine Sodium | Levothyroxine Sodium | 669 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 86 |
| Atenolol | Atenolol | 285 | 65 |
| Gabapentin | Gabapentin | 282 | 70 |
| Valsartan | Valsartan | 271 | 71 |
| Lisinopril | Lisinopril | 238 | 65 |
| Glipizide | Glipizide | 237 | 59 |
| Eliquis | Apixaban | 232 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 227 | 64 |
| Metformin Hcl | Metformin Hcl | 215 | 55 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 203 | 35 |
| Furosemide | Furosemide | 201 | 65 |
| Losartan Potassium | Losartan Potassium | 201 | 75 |
| Alprazolam | Alprazolam | 199 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 55 |
| Allopurinol | Allopurinol | 185 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 42 |
| Omeprazole | Omeprazole | 164 | 53 |
| Trazodone Hcl | Trazodone Hcl | 134 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 34 |
| Simvastatin | Simvastatin | 129 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 126 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 46 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 120 | 87 |
| Carvedilol | Carvedilol | 117 | 29 |
| Azithromycin | Azithromycin | 98 | 66 |
| Sertraline Hcl | Sertraline Hcl | 97 | 36 |
| Potassium Chloride | Potassium Chloride | 96 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 82 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 70 | 49 |
| Temazepam | Temazepam | 70 | 19 |
| Meloxicam | Meloxicam | 69 | 21 |
| Baclofen | Baclofen | 67 | 16 |
| Lorazepam | Lorazepam | 66 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 63 | suppressed |
| Clonazepam | Clonazepam | 63 | suppressed |
| Memantine Hcl | Memantine Hcl | 61 | 17 |
| Benazepril Hcl | Benazepril Hcl | 60 | 17 |
| Pregabalin | Pregabalin | 60 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 22 |
| Finasteride | Finasteride | 53 | 16 |
| Spironolactone | Spironolactone | 51 | 16 |
| Cephalexin | Cephalexin | 49 | 36 |
| Synthroid | Levothyroxine Sodium | 49 | 17 |
| Donepezil Hcl | Donepezil Hcl | 48 | 12 |
| Methylprednisolone | Methylprednisolone | 48 | 39 |
| Montelukast Sodium | Montelukast Sodium | 48 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 15 |
| Prednisone | Prednisone | 48 | 18 |
| Nystatin | Nystatin | 47 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 11 |
| Irbesartan | Irbesartan | 44 | 11 |
| Ezetimibe | Ezetimibe | 43 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 40 | suppressed |
| Lovastatin | Lovastatin | 40 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | 18 |
| Tramadol Hcl | Tramadol Hcl | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Alogliptin | Alogliptin Benzoate | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | 11 |
| Diazepam | Diazepam | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | 11 |
| Famotidine | Famotidine | 29 | 14 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | 13 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | 11 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 24 |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 16 |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 12 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 17 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Imipenem-Cilastatin Sodium | Imipenem/Cilastatin Sodium | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $125.00 · 1 records | AstraZeneca Pharmaceuticals LP | BREZTRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error